Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Breast cancer in the 21st century: Neu opportunities and neu challenges
Autore:
Schnitt, SJ;
Indirizzi:
Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr Boston MA USA 02215 l, Boston, MA 02215 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA
Titolo Testata:
MODERN PATHOLOGY
fascicolo: 3, volume: 14, anno: 2001,
pagine: 213 - 218
SICI:
0893-3952(200103)14:3<213:BCIT2C>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-SITU HYBRIDIZATION; TRASTUZUMAB HERCEPTIN; HER-2/NEU; IMMUNOHISTOCHEMISTRY; MICROARRAYS;
Keywords:
breast cancer; HER2/neu; erb-2; prognosis; immunohistochemistry; fluorescence in situ hybridization;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Schnitt, SJ Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,East Campus,Boston, MA 02215 USA Beth Israel Deaconess Med Ctr 330 Brookline Ave,East Campus Boston MA USA 02215
Citazione:
S.J. Schnitt, "Breast cancer in the 21st century: Neu opportunities and neu challenges", MOD PATHOL, 14(3), 2001, pp. 213-218

Abstract

Recent advances in the understanding of the molecular and genetic alterations underlying breast cancer development and progression have provided the opportunity to develop novel therapeutic strategies for this disease. None of these developments has had a greater recent impact on clinicians and pathologists than the recognition of the importance of the HER-2/neu (c-erbB-2) oncogene, Located on chromosome 17, this gene encodes a 185 kD transmembrane glycoprotein with tyrosine kinase activity that functions as a growth factor receptor. Amplification or overexpression of HER-B/neu is seen in approximately 20 to 30% of invasive breast cancers and this has been considered to be an adverse prognostic factor in many studies. However, recent interest in HER-2/neu has largely been focused on its role as a potential targetfor breast cancer treatment. In particular, recognition of the role of HER2/neu in breast cancer growth led to the development of a humanized monoclonal antibody directed against the HER-2/neu protein as a therapeutic agent (Herceptin). Clinical studies have further suggested that HER-2/neu status can provide important information regarding sensitivity to certain forms ofconventional systemic therapy, particularly anthracyclines, As a result ofthese developments, there has been increasing demand for pathologists to perform assays for HER-2/neu on current and archived breast cancer specimens. Immunohistochemistry and fluorescence in situ hybridization have emerged as the most viable assays for evaluation of HER-2/neu in routine clinical practice. However, each of these methods has its advantages and disadvantages. Determining the relative merits of these assays and developing clinically meaningful and reproducible systems to report the results are challenges pathologists must now address,The development of a therapeutic agent that directly targets a protein involved in a growth-signaling pathway representsa new paradigm in breast cancer treatment. Therapeutic strategies that target other molecules involved in breast cancer development and progression are on the horizon, It is crucial that pathologists become aware of these advances and assume a pivotal role in the development and application of assays to evaluate these new molecular targets.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 18:37:04